Literature DB >> 20401687

Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity.

Alan H Lazarus1.   

Abstract

Intravenous immunoglobulin (IVIG) is an effective treatment for a variety of autoimmune and inflammatory conditions. The mechanism of action of IVIG remains poorly understood, but a variety of theories have been suggested. Recent studies in murine models have indicated that some of the ameliorative effects of IVIG in autoimmunity can be repeated by the adoptive transfer of leukocytes that have been primed with IVIG. The active cell component within the leukocyte cell population in immune thrombocytopenia (ITP) was determined to be CD11c(+) dendritic cells. This review will highlight recent work in murine systems that indicates that the effects of IVIG can be adoptively transferred in some autoimmune diseases and inflammatory states.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20401687     DOI： 10.1007/s10875-010-9410-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  16 in total

Review 1.  The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

Authors:  Andrew R Crow; Alan H Lazarus
Journal:  Transfus Med Rev       Date:  2008-04

2.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

3.  Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells.

Authors:  K Shioji; C Kishimoto; S Sasayama
Journal:  Circ Res       Date:  2001-09-14       Impact factor: 17.367

4.  Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D).

Authors:  A Salama; V Kiefel; R Amberg; C Mueller-Eckhardt
Journal:  Blut       Date:  1984-07

5.  Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.

Authors:  J L Teeling; T Jansen-Hendriks; T W Kuijpers; M de Haas; J G van de Winkel; C E Hack; W K Bleeker
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.

Authors:  Renée Bazin; Réal Lemieux; Tony Tremblay
Journal:  Br J Haematol       Date:  2006-08-22       Impact factor: 6.998

7.  Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

Authors:  Vinayakumar Siragam; Davor Brinc; Andrew R Crow; Seng Song; John Freedman; Alan H Lazarus
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

8.  Administration of high-dose intact immunoglobulin has an anti-resorption effect in a mouse model of reproductive failure.

Authors:  Masamitsu Takeda; Hideto Yamada; Kazuya Iwabuchi; Shigeki Shimada; Makoto Naito; Noriaki Sakuragi; Hisanori Minakami; Kazunori Onoé
Journal:  Mol Hum Reprod       Date:  2007-08-31       Impact factor: 4.025

9.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

10.  Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.

Authors:  Amal Ephrem; Souleima Chamat; Catherine Miquel; Sylvain Fisson; Luc Mouthon; Giuseppina Caligiuri; Sandrine Delignat; Sriramulu Elluru; Jagadeesh Bayry; Sebastien Lacroix-Desmazes; José L Cohen; Benoît L Salomon; Michel D Kazatchkine; Srini V Kaveri; Namita Misra
Journal:  Blood       Date:  2007-10-11       Impact factor: 22.113
View more
  2 in total

1.  Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations.

Authors:  Mohan S Maddur; Meenu Sharma; Pushpa Hegde; Sébastien Lacroix-Desmazes; Srini V Kaveri; Jagadeesh Bayry
Journal:  J Clin Immunol       Date:  2012-08-07       Impact factor: 8.317

2.  Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.

Authors:  Andrew R Crow; Honghui Yu; Dongji Han; Alan H Lazarus
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.